BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?

Cardiol Therapeutics: Get in now after successful capital increase?

In addition to vaccines, drugs are the great hope for getting the Corona pandemic under control. So far, there is no approved drug with proven efficacy. Cardiol Therapeutics (Cardiol) is researching such a drug for COVID-19 patients and has reached an important milestone. The US FDA approved the treatment of hospitalized COVID-19 patients with CardiolRX, Cardiol's main product, as part of a clinical study. The Canadian Company is also researching a compound related to acute myocarditis and regeneration of the heart muscle. Currently, this is in phase 2.

It is well known that research costs money. Nevertheless, Cardiol's recent capital increase caught investors on the wrong foot. Although the issuance was placed within a few hours and the Company received about USD 50 million, the share price dropped significantly and is currently quoted at CAD 2.60. As a result, the share has lost around 50% of its value within 4 weeks. However, progress is being made in drug development. According to the experts at GBC Research, this is a good time to buy. Following the capital increase, the analyst house from Augsburg has again recommended the Cardiol share as a buy. The experts believe study results for the COVID-19 drug will be released in the fourth quarter of 2021 or the first quarter of 2022. GBC's price target for the Cardiol share is CAD 17.49, considerably higher than the current price.

Valneva: Recovery after the Flash Crash?

The Valneva share caused astonishment on Tuesday. Within less than half an hour, the share price plummeted from over EUR 21 to as low as EUR 17.66. But there was positive news. Valneva and the EU Commission signed the contract for the supply of Valneva's COVID-19 vaccine VLA2001. According to the agreement, the French Company is to supply 24.3 million doses of the vaccine in the second and third quarters of 2022. A total of up to 60 million doses are to be supplied in 2022 and 2023. The prerequisite is that the vaccine is approved. Study results published to date have been positive. Many hopes rest on VLA2001 to increase the vaccination rate in Germany and other countries. This is because it is an inactivated vaccine. The vaccine is based on the virus in its natural form, which is chemically inactivated and cannot reproduce in the vaccinated person's body. However, upon contact, the body reacts with the same immune response as the active coronavirus and forms antibodies.

BioNTech: Boosters and compulsory vaccinations drive the share price up

Things are currently going well at BioNTech. The share has left its correction behind and is once again setting its sights on the EUR 300 mark. Booster vaccinations are picking up speed. In Germany alone, Health Minister Jens Spahn had to order additional doses. Demand has risen insanely in the past two weeks, Spahn said, and they will deliver 6 million BioNTech doses starting this week alone. But there is more good news for BioNTech. Because soon, children as young as five could also be vaccinated in Europe. Today, the European Medicines Agency (EMA) is expected to decide whether to approve BioNTech's vaccine for children in this age group. So far, there is no Corona vaccine approved for children under the age of twelve in the EU. This mixed situation should give the BioNTech share further impetus.

COVID-19 continues to keep the world busy. Vaccine manufacturers like BioNTech and Valneva are benefiting. Effective drugs will also become cash cows, and Cardiol is going full throttle to develop one.